Abstract 784P
Background
Choriocarcinoma (CC) is a rare and highly aggressive cancer that exists in both the gestational (GCC) and non-gestational (NGCC) forms. Our research focused on comparing clinical outcomes, response to therapy, and prognostic determinants between these subtypes.
Methods
We analyzed data from the SEER database of patients diagnosed with CC between 2000 and 2020. Patients who were not diagnosed based on histology, previous history of cancer or other concurrent malignancies, or unknown data were excluded. The chi-square test were used for clinical features comparison. Kaplan-Meier estimation, log-rank tests, and Cox regression analyses were used to identify prognostic factors for overall survival (OS) and cancer specific survival (CSS). A nomogram was developed to predict 5-year OS, and a calibration curve was plotted to evaluate the agreement between the actual (observed) outcomes and expected probabilities.
Results
Of the 719 patients studied, 520 had GCC, and 200 had NGCC. Younger individuals were more common in the GCC. Additionally, a higher percentage of patients with NGCC were married (63.0% vs. 52.6%). AJCC stage distribution also differed; 47.4% of GCC patients were at stage I compared to 6.0% of NGCC patients. The surgery rates were higher in the NGCC group (79.5% vs. 60.9%). Patients with GCC had better OS than those with NGCC (93% vs. 71.2%, p = 0.001). CSS rates were 66.8% for NGCC and 65.2% for GCC (p = 0.001).
We developed a prognostic nomogram that integrated significant variables from multivariate analysis. For GCC, the model assigned the highest weight to radiation, followed by metastasis, and marital status. The AUC was 0.711 (95% CI: 0.64–0.79), and the calibration curves exhibited a mean error of 0.015. The NGCC model assigned the highest weights to metastasis, chemotherapy, and age. The AUC was 0.837 (95% CI, 0.77–0.9), and the calibration curve for 5-year survival demonstrated a mean error of 0.01.
Conclusions
Our study highlights the significant clinical and survival differences between GCC and NGCC patients. We developed prognostic nomograms tailored to each subtype to enhance prediction and support personalized management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
772P - Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (C-PATROL): Analysis by BRCA mutation status from a real-world study
Presenter: Jalid Sehouli
Session: Poster session 02
773P - Role of tumor primary chemosensitivity assessed by modeled CA-125 KELIM to predict complete interval debulking surgery (IDS) in ovarian carcinoma patients treated with neo-adjuvant chemotherapy and immunotherapy: A GINEGEPS/GINECO study of the NeoPembrOv and INeOV trials
Presenter: Pauline Corbaux
Session: Poster session 02
774P - Initial management and long-term outcome of ovarian clear cell carcinoma (OCCC) in the French multicentre ESME database
Presenter: Morgan Zenatri
Session: Poster session 02
775P - Association between chemotherapy response score (CRS) and tumour homologous recombination deficiency (tHRD) in women with newly diagnosed FIGO stage IIIC/IV high-grade serous ovarian cancer (HGSOC)
Presenter: Fiona Britton
Session: Poster session 02
776P - Liquid biopsy for the determination of homologous recombination deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study
Presenter: Alexandre Harlé
Session: Poster session 02
777P - A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)
Presenter: Katsutoshi Oda
Session: Poster session 02
778P - Efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure: A prospective, open label, single-arm, phase II study
Presenter: Jianqing Zhu
Session: Poster session 02
779P - Testing unselected women with newly diagnosed high-grade serous ovarian cancer (HGSOC) for germline pathogenic variants (PVs) in mismatch repair (MMR) genes is unnecessary
Presenter: Laura Spurgeon
Session: Poster session 02
780P - Propensity-score matching analysis for efficacy of platinum-based versus non-platinum chemotherapy in patients with “platinum-resistant” ovarian cancer (PROC): Real-world recent cohort study
Presenter: Alexey Rumyantsev
Session: Poster session 02
781P - Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups
Presenter: Frederik Marmé
Session: Poster session 02